Table 5.
Comparison of Pulmonary arterial hypertension patients in PROKERALA registry with other registries. CHD-PH = Congenital heart disease associated pulmonary hypertension, CTD-PH = Connective tissue disorder associated pulmonary hypertension, PAH = Pulmonary arterial hypertension, DC = Dual combination therapy, FC = Functional class, KORPAH = Korean Registry of Pulmonary Arterial Hypertension, REHAP = Spanish Registry of Pulmonary Arterial Hypertension.
| PROKERALA | GIESSEN | ASPIRE | French | Swiss | REHAP | REVEAL | KORPAH | |
|---|---|---|---|---|---|---|---|---|
| PAH population, n | 317 | 685 | 600 | 674 | 549 | 866 | 2716 | 625 |
| Female gender, % | 62.6 | 65 | 70 | 65 | 60 | 71 | 79 | 80 |
| Mean age, years | 51 | 50 | 50 | 57 | 45 | 50 | 48 | |
| Type of PAH, % | ||||||||
| Idiopathic | 75 | 43 | 29 | 39 | 60 | 36 | 47 | 23 |
| CHD-PH | 22 | 21 | 31 | 15 | 18 | 18 | 24 | 50 |
| CTD-PH | 3 | 13 | 33 | 11 | 8 | 19 | 12 | 25 |
| Baseline FC, % | ||||||||
| II | 63 | 19 | – | – | 24 | 38 | 38 | 35 |
| III | 23 | 59 | 64 | 75(III and IV) | 57 | 48 | 48 | 38 |
| IV | 3 | 22 | 14 | – | 17 | 5 | 5 | 5 |
| Treatment, % | ||||||||
| Monotherapy | 26.5 | 72 | 59 | – | 59 | – | – | 49 |
| DC | 4.4 | 15 | – | – | 10 | – | 40 | 12 |
| Survival at 1 year, % | 98 | 88 | 88 | 88 | 87 | 86 | 91 | 91 |